SEC Form 6-K filed by Biodexa Pharmaceuticals plc American Depositary Shs
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
For the month of September 2025
Commission File Number
(Translation of registrant’s name into English)
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
On September 12, 2025, Biodexa Pharmaceuticals PLC (the “Company”) issued a press release announcing its financial and operating results for the six months ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The information set forth in the press release under the headings “Chief Executive’s Review,” “1H25 Financial Review” and the Consolidated Unaudited Interim Financial Statements for the six month period ended June 30, 2025 and the notes thereto shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Number 333-209365) and Form F-3 (Registration Number 333-267932) of the Company (including any prospectuses forming part of such registration statements) and be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
Other than as set forth herein, the information in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.
SUBMITTED HEREWITH
Attached to the Registrant’s Form 6-K filing for the month of September 2025, and incorporated by reference herein, is:
|
Exhibit No. |
Description | |
| 99.1 | Press Release, dated September 12, 2025 | |
| 101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | |
| 101.SCH | INLINE XBRL Taxonomy Extension Schema Document. | |
| 101.DEF | INLINE XBRL Taxonomy Extension Calculation Linkbase Document. | |
| 101.CAL | INLINE XBRL Taxonomy Extension Definition Linkbase Document. | |
| 101.LAB | INLINE XBRL Taxonomy Extension Label Linkbase Document. | |
| 101.PRE | INLINE XBRL Taxonomy Extension Presentation Linkbase Document. | |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Biodexa Pharmaceuticals PLC | ||
| Date: September 12, 2025 | By: | /s/ Stephen Stamp |
| Stephen Stamp | ||
| Chief Executive Officer and Chief Financial Officer | ||